Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Mibavademab · REGN-4461

Other · developed by REGENERON PHARMACEUTICALS

Phase 3 Most advanced trial
REGN Developer
1 Registered trials

What is Mibavademab?

Mibavademab (REGN4461) is an investigational agent studied in monogenic obesity.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
REGN-4461
Drug type
Other
Therapy area
Metabolic
Developer
REGENERON PHARMACEUTICALS (REGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
PHL2UDY3AB

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07220772 Phase 3 Monogenic Obesity Recruiting REGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Monogenic Obesity

More from REGENERON PHARMACEUTICALS

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the REGN page.

Follow REGN, the company behind Mibavademab

See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

REGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.